Table 1.

Regulatory agency recommendations for NOACs in patients with CKD

AgencyDrug
ApixabanDabigatranRivaroxaban
Health CanadaAtrial fibrillation and VTE:Atrial fibrillation:Atrial fibrillation:
 CrCl=30–50 ml/min: No dose adjustment required; i.e., 5 mg orally twice daily except for: CrCl=30–50 ml/min: 150 mg orally twice daily CrCl=30–49 ml/min: 15 mg orally once daily
 Cr>132 µmol/L Contraindicated if CrCl<30 ml/min Contraindicated if CrCl<30 ml/min
 Age>80 yr
  Weight <60 kgVTE:
 (if any of the above, use 2.5 mg orally twice daily) CrCl=30–49 ml/min: 15 mg orally twice daily×21 d, then 20 mg orally once daily
 Contraindicated if CrCl<25 ml/min Contraindicated if CrCl<30 ml/min
US Food and Drug AdministrationAtrial fibrillation and VTE:Atrial fibrillation and VTE:Atrial fibrillation:
 CrCl=30–50 ml/min: No dose adjustment required; i.e., 5 mg orally twice daily except for: CrCl>30 ml/min: 150 mg orally twice daily CrCl=30–49 ml/min: 15 mg orally once daily
 CrCl=15–30 ml/min: 75 mg orally twice daily CrCl=15–29 ml/min: 15 mg orally once daily
 
 Cr >132 µmol/L Contraindicated if CrCl<15 ml/min
 Age>80 yr Contraindicated if CrCl<15ml/min
 Weight<60 kgVTE:
 (if any of the above, use 2.5 mg orally twice daily) CrCl=30–49 ml/min: 15 mg orally twice daily×21 d then 20 mg orally once daily
 Contraindicated if CrCl<15 ml/min Contraindicated if CrCl<30 ml/min